查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1412402

多形性胶质母细胞瘤治疗药物市场：按类型、最终用户划分 - 全球预测 2024-2030

Glioblastoma Multiforme Treatment Market by Type (Chemotherapy, Combined Modality Therapy, Medications), End-Users (Hospitals, Speciality Centers) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年多形性胶质母细胞瘤治疗市场规模为31.1亿美元，2024年达33.6亿美元，2030年达53.9亿美元，复合年增长率为8.17%。

多形性胶质母细胞瘤治疗的全球市场

主要市场统计
基准年[2023] 31.1亿美元
预测年份 [2024] 33.6亿美元
预测年份 [2030] 53.9亿美元
复合年增长率（%） 8.17%
多形性胶质母细胞瘤治疗药物市场-IMG1

FPNV定位矩阵

FPNV定位矩阵对于评估多形性胶质母细胞瘤药物市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出资讯的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可对多形性胶质母细胞瘤治疗市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵考察，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更资讯的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场并分析其在成熟细分市场的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-多形性胶质母细胞瘤治疗市场的市场规模与预测是多少？

2-在多形性胶质母细胞瘤治疗药物市场的预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3-多形性胶质母细胞瘤治疗市场的技术趋势和法律规范是什么？

4-多形性胶质母细胞瘤治疗药物市场主要供应商的市场占有率为何？

5-进入多形性胶质母细胞瘤药物市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 脑部和神经系统疾病盛行率上升
      • 提高对脑​​部疾病和肿瘤的早期发现和治疗的认识
      • 改善整个经济领域的医疗基础设施
    • 抑制因素
      • 治疗多形性神经胶母细胞瘤的高费用和併发症
    • 机会
      • 加大投入加速临床研究
      • 治疗多形性神经胶母细胞瘤新技术的出现
    • 任务
      • 与多形性胶质母细胞瘤药物相关的报销问题和严格的监管合规性
  • 市场区隔分析
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章多形性胶质母细胞瘤治疗药物市场：依类型

  • 化疗
  • 综合疗法
  • 药品
  • 放射治疗
  • 外科手术
  • 标靶治疗

第七章多形性胶质母细胞瘤治疗药物市场：依最终使用者分类

  • 医院
  • 专业中心

第八章美洲多形性胶质母细胞瘤治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太多形性胶质母细胞瘤治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲多形性胶质母细胞瘤治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析

第12章竞争产品组合

  • 主要公司简介
    • AIVITA Biomedical, Inc.
    • Angiochem Inc.
    • Avant Immunotherapeutics, Inc.
    • Bayer AG
    • Chimerix Inc.
    • Daiichi Sankyo Company, Limited
    • Diffusion Pharmaceuticals Inc.
    • DNAtrix, Inc.
    • Eisai Co., Ltd.
    • F. Hoffmann-La Roche Ltd
    • Karyopharm Therapeutics Inc.
    • Kazia Therapeutics Limited
    • Lineage Cell Therapeutics, Inc.
    • Merck & Co. Inc.
    • Moleculin Biotech, Inc.
    • Novocure GmbH
    • OncoSynergy, Inc.
    • Pfizer Inc.
    • Sapience Therapeutics, Inc.
    • SonALAsense
    • Sumitomo Dainippon Pharma Oncology, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • VBI Vaccines Inc.
    • VBL Therapeutics
  • 主要产品系列

第十三章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-C002B1C99723

[187 Pages Report] The Glioblastoma Multiforme Treatment Market size was estimated at USD 3.11 billion in 2023 and expected to reach USD 3.36 billion in 2024, at a CAGR 8.17% to reach USD 5.39 billion by 2030.

Global Glioblastoma Multiforme Treatment Market

KEY MARKET STATISTICS
Base Year [2023] USD 3.11 billion
Estimated Year [2024] USD 3.36 billion
Forecast Year [2030] USD 5.39 billion
CAGR (%) 8.17%
Glioblastoma Multiforme Treatment Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Glioblastoma Multiforme Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Glioblastoma Multiforme Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Glioblastoma Multiforme Treatment Market, highlighting leading vendors and their innovative profiles. These include AIVITA Biomedical, Inc., Angiochem Inc., Avant Immunotherapeutics, Inc., Bayer AG, Chimerix Inc., Daiichi Sankyo Company, Limited, Diffusion Pharmaceuticals Inc., DNAtrix, Inc., Eisai Co., Ltd., F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics Inc., Kazia Therapeutics Limited, Lineage Cell Therapeutics, Inc., Merck & Co. Inc., Moleculin Biotech, Inc., Novocure GmbH, OncoSynergy, Inc., Pfizer Inc., Sapience Therapeutics, Inc., SonALAsense, Sumitomo Dainippon Pharma Oncology, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., VBI Vaccines Inc., and VBL Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Glioblastoma Multiforme Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Chemotherapy
    • Combined Modality Therapy
    • Medications
    • Radiation Therapy
    • Surgery
    • Targeted Therapy
  • End-Users
    • Hospitals
    • Speciality Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Glioblastoma Multiforme Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Glioblastoma Multiforme Treatment Market?

3. What are the technology trends and regulatory frameworks in the Glioblastoma Multiforme Treatment Market?

4. What is the market share of the leading vendors in the Glioblastoma Multiforme Treatment Market?

5. Which modes and strategic moves are suitable for entering the Glioblastoma Multiforme Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Glioblastoma Multiforme Treatment Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of brain and neurological diseases
      • 5.1.1.2. Growing awareness of early detection and treatments related to brain disorders and tumors
      • 5.1.1.3. Improved healthcare infrastructure across economies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and complications associated with glioblastoma multiforme treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investments to foster clinical research
      • 5.1.3.2. Emerging new techniques to treat glioblastoma multiforme
    • 5.1.4. Challenges
      • 5.1.4.1. Reimbursement issues and stringent regulatory compliances associated with glioblastoma multiforme treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Glioblastoma Multiforme Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Combined Modality Therapy
  • 6.4. Medications
  • 6.5. Radiation Therapy
  • 6.6. Surgery
  • 6.7. Targeted Therapy

7. Glioblastoma Multiforme Treatment Market, by End-Users

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Speciality Centers

8. Americas Glioblastoma Multiforme Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Glioblastoma Multiforme Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Glioblastoma Multiforme Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. AIVITA Biomedical, Inc.
    • 12.1.2. Angiochem Inc.
    • 12.1.3. Avant Immunotherapeutics, Inc.
    • 12.1.4. Bayer AG
    • 12.1.5. Chimerix Inc.
    • 12.1.6. Daiichi Sankyo Company, Limited
    • 12.1.7. Diffusion Pharmaceuticals Inc.
    • 12.1.8. DNAtrix, Inc.
    • 12.1.9. Eisai Co., Ltd.
    • 12.1.10. F. Hoffmann-La Roche Ltd
    • 12.1.11. Karyopharm Therapeutics Inc.
    • 12.1.12. Kazia Therapeutics Limited
    • 12.1.13. Lineage Cell Therapeutics, Inc.
    • 12.1.14. Merck & Co. Inc.
    • 12.1.15. Moleculin Biotech, Inc.
    • 12.1.16. Novocure GmbH
    • 12.1.17. OncoSynergy, Inc.
    • 12.1.18. Pfizer Inc.
    • 12.1.19. Sapience Therapeutics, Inc.
    • 12.1.20. SonALAsense
    • 12.1.21. Sumitomo Dainippon Pharma Oncology, Inc.
    • 12.1.22. Sun Pharmaceutical Industries Ltd.
    • 12.1.23. Teva Pharmaceutical Industries Ltd.
    • 12.1.24. VBI Vaccines Inc.
    • 12.1.25. VBL Therapeutics
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. GLIOBLASTOMA MULTIFORME TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLIOBLASTOMA MULTIFORME TREATMENT MARKET DYNAMICS
  • FIGURE 7. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 10. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINED MODALITY THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 13. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SPECIALITY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 101. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 102. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. GLIOBLASTOMA MULTIFORME TREATMENT MARKET LICENSE & PRICING